MDS Reports Third Quarter 2007 Results(Revenue EBITDA -------------------...),Health

-------------------------------------------------------------------------

Reported growth 24% 167%

Growth attributable to the acquisition of MD (21%) (71%)

Impact of currency fluctuations on growth - 94%

-------------------------------------------------------------------------

Organic growth 3% 190%

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Operating income for the third quarter of 2007 was $13 million compared to $5 million reported for the same period in 2006. Excluding the impact of MD, operating income for the 2007 quarter was $17 million, as both MDS Pharma Services and Sciex experienced solid growth in operating income compared to the prior year. Excluding the $2 million of the Zevalin(R) deferred revenue in the prior-year period, MDS Nordion operating income was level with 2006.

Adjusted EBITDA for the quarter was $56 million, compared to $21 million last year and $37 million reported for the second quarter of fiscal 2007. Adjusted EBITDA increased 167% on a reported basis. MDS Pharma Services demonstrated continued steady improvement in adjusted EBITDA, reporting sequential improvement in adjusted EBITDA for the fourth consecutive quarter. MDS Analytical Technologies also had a strong quarter on an adjusted EBITDA basis, both before and after the impact of the MD acquisition.

Adjustments reported for the quarter include $11 million of costs related to the integration of MDS Analytical Technologies, $10 million of which relates to amortization of fair value increments recorded for inventory and order backlog as part of the purchase accounting for MD. As at July 31, 2007, the fair value increments related to inventory and order
'/>"/>